Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Martin Miner
Pd50-06 Long-Term Safety and Tolerability of Oral Testosterone (Lpcn 1021) in Hypogonadal Men: Results From the 52-Week Phase 3 Study
Journal of Urology
Urology
Related publications
Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
Headache
Neurology
Revefenacin, a Once-Daily, Lung-Selective, Long-Acting Muscarinic Antagonist for Nebulized Therapy: Safety and Tolerability Results of a 52-Week Phase 3 Trial in Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Respiratory Medicine
Pulmonary
Respiratory Medicine
Comparison of Long-Acting Testosterone Undecanoate Formulation Versus Testosterone Enanthate on Sexual Function and Mood in Hypogonadal Men
European Journal of Endocrinology
Medicine
Endocrinology
Metabolism
Diabetes
Longer-Term Safety and Efficacy Measures of AR101 Oral Immunotherapy for Peanut Allergy: Results From a Phase 3 Follow-On Study
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Long-Term Efficacy and Safety of Brodalumab in the Treatment of Psoriasis: 120-Week Results From the Randomized, Double-Blind, Placebo- And Active Comparator–controlled Phase 3 AMAGINE-2 Trial
Journal of the American Academy of Dermatology
Dermatology
Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (The TIMES2 Study)
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Erratum To: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results From an Open-Label, 48-Week Extension Study
Clinical Drug Investigation
Medicine
Pharmacology
Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results From 2 Randomized Phase-Iii Studies and 1 Open-Label Long-Term Extension Study
Journal of the American Academy of Dermatology
Dermatology
